United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by USA Financial Formulas

USA Financial Formulas boosted its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 856.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 870 shares of the biotechnology company's stock after purchasing an additional 779 shares during the period. USA Financial Formulas' holdings in United Therapeutics were worth $307,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of UTHR. Meiji Yasuda Asset Management Co Ltd. increased its stake in shares of United Therapeutics by 1.6% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company's stock worth $652,000 after purchasing an additional 33 shares during the last quarter. Toronto Dominion Bank lifted its position in United Therapeutics by 0.8% in the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company's stock worth $1,441,000 after buying an additional 37 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of United Therapeutics by 0.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company's stock worth $1,761,000 after buying an additional 39 shares during the period. Benjamin F. Edwards & Company Inc. lifted its position in United Therapeutics by 14.0% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company's stock valued at $109,000 after purchasing an additional 42 shares during the last quarter. Finally, First Citizens Bank & Trust Co. grew its holdings in United Therapeutics by 1.8% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company's stock worth $961,000 after acquiring an additional 48 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Trading Down 2.2 %

UTHR traded down $8.19 during trading on Friday, hitting $358.20. The company's stock had a trading volume of 144,288 shares, compared to its average volume of 251,352. The firm has a market capitalization of $15.99 billion, a price-to-earnings ratio of 15.73, a P/E/G ratio of 0.93 and a beta of 0.57. The business's fifty day simple moving average is $368.42 and its 200 day simple moving average is $353.46. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million during the quarter, compared to analysts' expectations of $722.62 million. During the same period in the prior year, the business posted $5.38 earnings per share. The firm's revenue for the quarter was up 22.9% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Louis W. Sullivan sold 26,209 shares of the business's stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James Edgemond sold 7,800 shares of the firm's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $350.00, for a total value of $2,730,000.00. Following the completion of the transaction, the chief financial officer now owns 6,978 shares in the company, valued at $2,442,300. The trade was a 52.78 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 144,630 shares of company stock worth $54,371,916. Corporate insiders own 11.90% of the company's stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of research analyst reports. UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Jefferies Financial Group lifted their price objective on United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday. The Goldman Sachs Group increased their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research note on Friday, November 1st. Finally, Argus boosted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $378.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.